康希諾生物(06185.HK):正推動Ad5-nCoV國際多中心III期臨試 目前尚未入組
格隆匯8月18日丨康希諾生物-B(06185.HK)公佈,公司注意到公司股票價格波動以及部分媒體有關重組新型冠狀病毒疫苗(腺病毒載體)(“Ad5-nCoV”)進展的報導。為免對公司股東及潛在投資者產生誤導,公司作出澄清及聲明如下:
1. 公司於2020年8月11日收到“一種以人複製缺陷腺病毒為載體的重組新型冠狀病毒疫苗”的授予發明專利權通知書。該專利由中國人民解放軍軍事科學院軍事醫學研究院與公司聯合申請;及
2. Ad5-nCoV的II期臨牀試驗已完成。公司目前正在與多個國家聯繫,計劃儘快推動Ad5-nCoV國際多中心III期臨牀試驗。截至目前,Ad5-nCoV的III期臨牀試驗尚未入組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.